UP!
 |
|
|
Type
|
Public |
|---|---|
| Traded as | NYSE: CNC S&P 500 Component |
| Industry | Healthcare |
| Founded | 1984 |
| Headquarters | St. Louis, MO, U.S. |
| Revenue |  US$ 40.60 billion (2016) |
|
Operating income
|
US$ 558 million (2016) |
|
Net income
|
US$ 562 million (2016) |
| Total assets | US$ 20.20 billion (2016) |
|
Number of employees
|
30,500 (2016) |
| Website | www |
Centene Corporation is a large publicly-traded company and a leading multi-line healthcare enterprise that serves as a major intermediary for both government-sponsored and privately-insured health care programs. The main lines of Centene include Medicare, Medicaid, The Health Insurance Marketplace System, (via the ACA), Tricare, as well as traditional commercial insurance. It is the second-largest publicly-traded corporation in the state of Missouri.
Centene also contracts with other healthcare and commercial organizations to provide specialty services, including behavioral health care services, case management software, correctional insurance, in-home health services, life and health management, vision, pharmacy benefits management, and telehealth services.
Founded as a single health plan in Wisconsin in 1984, Centene has established itself as a national leader in healthcare services. Chairman, President and CEO Michael F. Neidorff joined the company in 1996.
Over the past 33 years, Centene has grown to become a $40 billion member of the Fortune 500 trading on the New York Stock Exchange. With over 31,000 employees across the country, Centene operates health plans that serve 12.3 million members in 29 states and 2 international markets and offers a full range of health insurance solutions to other healthcare and commercial organizations.
July 2, 2015, Centene announced it would acquire Health Net. At announcement, it was estimated Health Net shareholders would own 29% of the combined company. March 2016, the merger was finalized and Health Net shareholders received 0.622 shares of Centene common stock and $28.25 in cash for each share at closing, making the total transaction value about $6 billion, including assumption of debt. After its acquisition of Health Net, Centene now provides healthcare to over 11 million people.
Centene currently ranks #66 on the Fortune 500 & #244 on the Fortune Global 500 List." On September 12, 2017, it was announced that Centene Corp. would acquire the nonprofit insurer Fidelis Care for US $3.75 billion.
Centene's health plans provide education and outreach programs.
In 2014, Superior HealthPlan of Texas was alleged to have denied coverage of an infant's surgery for brain cancer at Texas Children's Hospital where it has been alleged to have previously paid claims for the infant. Part of the source of the controversy lies in reports that that facility has a notably higher survival rate for such operations. Superior HealthPlan claims that it does not cover Texas Children's Hospital and that it has directed the family to a different facility. Superior HealthPlan said it was "confident" the family would find capable in-network providers.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q4 2022 | 2023-02-07 | Future report Set alerts | |
| Q3 2022 | 2022-10-25 | 1.30 | 1.30 |
| Q2 2022 | 2022-07-26 | 1.77 | 1.77 |
| Q1 2022 | 2022-04-26 | 1.83 | 1.83 |
| Q4 2021 | 2022-02-08 | 1.01 | 1.01 |
| Q3 2021 | 2021-10-26 | 1.26 | 1.26 |
| Q2 2021 | 2021-07-27 | 1.25 | 1.25 |
| Q1 2021 | 2021-04-27 | 1.63 | 1.63 |
| Q4 2020 | 2021-02-09 | 0.46 | 0.46 |
| Q3 2020 | 2020-10-27 | 1.26 | 1.26 |
| 2016-06-29 | Upgrade | Morgan Stanley | Equal Weight to Overweight | $84.00 to $86.00 |
| 2016-06-28 | Initiated Coverage | Wolfe Research | Market Perform | $80.00 |
| 2016-06-28 | Reiterated Rating | Credit Suisse | Buy | |
| 2016-06-28 | Reiterated Rating | Credit Suisse Group AG | Buy | |
| 2016-06-20 | Reiterated Rating | Cowen and Company | Buy | |
| 2016-06-20 | Reiterated Rating | Wells Fargo | Buy | |
| 2016-06-20 | Reiterated Rating | Leerink Swann | Outperform | $78.00 to $80.00 |
| 2016-06-20 | Reiterated Rating | Oppenheimer | Outperform | $89.00 |
| 2016-06-20 | Reiterated Rating | FBR & Co. | Buy | |
| 2016-06-20 | Upgrade | Barclays | Equal Weight to Overweight | $76.00 to $82.00 |
| 2016-06-20 | Reiterated Rating | Wells Fargo & Co. | Buy | |
| 2016-06-20 | Reiterated Rating | Oppenheimer Holdings Inc. | Outperform | $89.00 |
| 2016-06-20 | Reiterated Rating | FBR & Co | Buy | |
| 2016-06-20 | Upgrade | Barclays PLC | Equal Weight to Overweight | $76.00 to $82.00 |
| 2016-06-16 | Initiated Coverage | Sanford C. Bernstein | Underperform to Market Perform | $76.00 |
| 2016-06-08 | Reiterated Rating | Jefferies Group | Buy | $80.00 |
| 2016-06-04 | Reiterated Rating | Cantor Fitzgerald | Buy | |
| 2016-06-01 | Boost Price Target | Barclays | Equal Weight | $70.00 to $72.00 |
| 2016-05-26 | Upgrade | Stifel Nicolaus | Hold to Buy | $75.00 |
| 2016-05-24 | Reiterated Rating | Oppenheimer | Buy | $89.00 |
| 2016-05-12 | Reiterated Rating | Leerink Swann | Buy | |
| 2016-04-29 | Reiterated Rating | Wedbush | Outperform | $80.00 |
| 2016-04-27 | Reiterated Rating | Cantor Fitzgerald | Buy | |
| 2016-04-27 | Reiterated Rating | Morgan Stanley | Hold | |
| 2016-04-25 | Initiated Coverage | Cowen and Company | Outperform | $70.00 |
| 2016-04-05 | Reiterated Rating | Jefferies Group | Buy | $80.00 |
| 2016-04-02 | Reiterated Rating | Citigroup Inc. | Buy | |
| 2016-03-28 | Boost Price Target | Credit Suisse | $70.00 to $72.00 | |
| 2016-03-24 | Boost Price Target | Credit Suisse | Neutral to Outperform | $102.00 to $118.00 |
| 2016-03-24 | Reiterated Rating | Oppenheimer | Buy | $89.00 |
| 2016-02-11 | Reiterated Rating | Oppenheimer | Outperform | $89.00 |
| 2016-02-11 | Reiterated Rating | FBR & Co. | Outperform | $90.00 |
| 2016-02-11 | Reiterated Rating | Wedbush | Outperform | $80.00 |
| 2016-02-10 | Lower Price Target | Barclays | Equal Weight | $72.00 to $64.00 |
| 2016-02-09 | Reiterated Rating | Cantor Fitzgerald | Buy | $90.00 |
| 2016-01-27 | Reiterated Rating | Oppenheimer | Outperform | $89.00 |
| 2016-01-26 | Reiterated Rating | FBR & Co. | Outperform | |
| 2016-01-08 | Reiterated Rating | Jefferies Group | Buy | $75.00 to $80.00 |
| 2016-01-06 | Boost Price Target | Barclays | Equal Weight | $70.00 to $72.00 |
| 2015-12-29 | Reiterated Rating | Cantor Fitzgerald | Buy | |
| 2015-12-23 | Reiterated Rating | Cantor Fitzgerald | Buy | $90.00 |
| 2015-12-22 | Boost Price Target | Credit Suisse | Outperform | $65.00 to $79.00 |
| 2015-12-21 | Reiterated Rating | FBR & Co. | Buy | $90.00 |
| 2015-12-21 | Boost Price Target | Leerink Swann | Outperform | $75.00 to $78.00 |
| 2015-12-21 | Boost Price Target | Jefferies Group | Buy | $73.00 to $75.00 |
| 2015-12-21 | Boost Price Target | Citigroup Inc. | Buy | $72.00 to $76.00 |
| 2015-12-17 | Reiterated Rating | Cantor Fitzgerald | Buy | $85.00 |
| 2015-12-16 | Initiated Coverage | Credit Suisse | Outperform | $65.00 |
| 2015-12-15 | Reiterated Rating | Jefferies Group | Buy | $88.00 to $73.00 |
| 2015-10-28 | Lower Price Target | Barclays | Equal Weight | $81.00 to $70.00 |
| 2015-10-19 | Reiterated Rating | Oppenheimer | Outperform | $89.00 |
| 2015-10-02 | Reiterated Rating | Cantor Fitzgerald | Buy | $85.00 |
| 2015-10-02 | Initiated Coverage | Citigroup Inc. | Buy | $65.00 |
| 2015-07-29 | Reiterated Rating | Cantor Fitzgerald | Buy | $85.00 |
| 2015-07-29 | Reiterated Rating | Oppenheimer | Outperform | $89.00 |
| 2015-07-21 | Downgrade | Goldman Sachs | Neutral to Sell | $73.00 to $69.00 |
| 2015-07-21 | Downgrade | Goldman Sachs Group Inc. | Neutral to Sell | $73.00 to $69.00 |
| 2015-07-15 | Upgrade | Jefferies Group | Hold to Buy | $88.00 |
| 2015-07-14 | Reiterated Rating | Cantor Fitzgerald | Buy | |
| 2015-07-13 | Upgrade | FBR & Co. | Market Perform to Outperform | $80.00 to $90.00 |
| 2015-07-08 | Upgrade | Wells Fargo & Co. | Market Perform to Outperform | |
| 2015-07-08 | Upgrade | Wells Fargo | Market Perform to Outperform | |
| 2015-07-06 | Reiterated Rating | Oppenheimer | Outperform | $89.00 |
| 2015-07-06 | Reiterated Rating | Cantor Fitzgerald | Buy | $85.00 |
| 2015-07-06 | Downgrade | Barclays | Overweight to Equal Weight | $88.00 to $81.00 |
| 2015-07-02 | Reiterated Rating | Barclays | Overweight to Overweight | $84.00 to $88.00 |
| 2015-06-22 | Boost Price Target | Oppenheimer | Outperform | $83.00 to $89.00 |
| 2015-06-15 | Set Price Target | Cantor Fitzgerald | Buy | $80.00 to $85.00 |
| 2015-06-15 | Boost Price Target | Deutsche Bank | Hold | $65.00 to $73.00 |
| 2015-06-15 | Reiterated Rating | Susquehanna | Positive | $85.00 to $87.00 |
| 2015-06-15 | Reiterated Rating | Wedbush | Outperform | $80.00 to $84.00 |
| 2015-06-15 | Boost Price Target | Leerink Swann | Outperform | $75.00 to $85.00 |
| 2015-06-15 | Boost Price Target | Barclays | Overweight | $84.00 to $88.00 |
| 2015-06-15 | Boost Price Target | Jefferies Group | Hold | $71.00 to $75.00 |
| 2015-06-15 | Boost Price Target | FBR & Co. | Market Perform | $75.00 to $80.00 |
| 2015-06-15 | Boost Price Target | Deutsche Bank AG | Hold | $65.00 to $73.00 |
| 2015-06-12 | Reiterated Rating | Oppenheimer | Outperform | $76.00 to $83.00 |
| 2015-05-13 | Reiterated Rating | Deutsche Bank | Hold | $65.00 |
| 2015-05-04 | Reiterated Rating | BMO Capital Markets | Outperform | $77.00 to $78.00 |
| 2015-04-29 | Set Price Target | Cantor Fitzgerald | Buy | $70.00 to $80.00 |
| 2015-04-28 | Boost Price Target | FBR & Co. | Market Perform | $55.00 to $75.00 |
| 2015-04-16 | Boost Price Target | Oppenheimer | Outperform | $63.00 to $76.00 |
| 2015-03-20 | Boost Price Target | Barclays | Overweight | $66.00 to $84.00 |
| 2015-02-25 | Set Price Target | Cantor Fitzgerald | Buy | $70.00 |
| 2015-02-24 | Lower Price Target | Barclays | Overweight | $132.00 to $66.00 |
| 2015-02-04 | Reiterated Rating | Deutsche Bank | Hold | $112.00 to $114.00 |
| 2015-02-04 | Set Price Target | Oppenheimer | Buy | $125.00 |
| 2015-02-04 | Boost Price Target | Wedbush | Outperform | $119.00 to $125.00 |
| 2015-01-26 | Set Price Target | Wedbush | Buy | $119.00 |
| 2015-01-08 | Boost Price Target | Barclays | Overweight | $120.00 to $132.00 |
| 2015-01-06 | Reiterated Rating | Deutsche Bank | Hold | $105.00 to $112.00 |
| 2015-01-06 | Upgrade | BMO Capital Markets | Market Perform to Outperform | $103.00 to $118.00 |
| 2014-12-16 | Boost Price Target | Credit Suisse | Outperform | $102.00 to $118.00 |
| 2014-12-15 | Boost Price Target | Deutsche Bank | Hold | $83.00 to $105.00 |
| 2014-12-15 | Boost Price Target | Bank of America | Buy | $114.00 to $120.00 |
| 2014-12-15 | Boost Price Target | Jefferies Group | Hold | $86.00 to $102.00 |
| 2014-12-15 | Boost Price Target | Barclays | Overweight | $102.00 to $120.00 |
| 2014-12-15 | Boost Price Target | RBC Capital | Outperform | $103.00 to $114.00 |
| 2014-12-15 | Boost Price Target | Bank of America Corp. | Buy | $114.00 to $120.00 |
| 2014-12-15 | Boost Price Target | Royal Bank Of Canada | Outperform | $103.00 to $114.00 |
| 2014-11-18 | Reiterated Rating | Bank of America | Buy | $104.00 to $114.00 |
| 2014-11-13 | Downgrade | FBR & Co. | Outperform to Market Perform | $90.00 |
| 2014-10-30 | Reiterated Rating | Credit Suisse | Outperform | $90.00 to $102.00 |
| 2014-10-29 | Boost Price Target | Oppenheimer | Outperform | $93.00 to $99.00 |
| 2014-10-29 | Reiterated Rating | Deutsche Bank | Hold | $77.00 to $83.00 |
| 2014-10-29 | Reiterated Rating | Barclays | Overweight | $96.00 to $102.00 |
| 2014-10-28 | Reiterated Rating | Citigroup Inc. | Sell | $69.00 to $71.00 |
| 2014-07-31 | Boost Price Target | Cantor Fitzgerald | Buy | $80.00 to $85.00 |
| 2014-07-29 | Boost Price Target | JPMorgan Chase & Co. | Neutral | $71.00 to $78.00 |
| 2014-07-25 | Downgrade | Wells Fargo & Co. | Outperform to Market Perform | |
| 2014-07-25 | Downgrade | Wells Fargo | Outperform to Market Perform | |
| 2014-07-23 | Boost Price Target | Barclays | Overweight | $84.00 to $96.00 |
| 2014-07-23 | Reiterated Rating | Citigroup Inc. | Outperform | $83.00 to $90.00 |
| 2014-07-23 | Reiterated Rating | S&P Equity Research | Buy | $89.00 to $94.00 |
| 2014-07-23 | Boost Price Target | Oppenheimer | Outperform | $89.00 to $93.00 |
| 2014-07-23 | Boost Price Target | Jefferies Group | Hold | $72.00 to $82.00 |
| 2014-07-22 | Boost Price Target | FBR & Co. | Outperform | $78.00 to $90.00 |
| 2014-07-16 | Reiterated Rating | Deutsche Bank | Hold | $70.00 to $74.00 |
| 2014-07-14 | Boost Price Target | Susquehanna | $85.00 to $88.00 | |
| 2014-06-27 | Initiated Coverage | Morgan Stanley | Buy | $87.00 |
| 2014-06-27 | Initiated Coverage | Sterne Agee CRT | Positive to Buy | $74.27 to $87.00 |
| 2014-06-26 | Boost Price Target | Oppenheimer | Outperform | $81.00 to $89.00 |
| 2014-06-16 | Reiterated | UBS | Buy | $73 to $79 |
| 2014-06-16 | Boost Price Target | Oppenheimer | Outperform | $78.00 to $81.00 |
| 2014-06-16 | Reiterated Rating | Credit Suisse | Outperform | $72.00 to $83.00 |
| 2014-06-16 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | $69.00 to $71.00 |
| 2014-06-16 | Boost Price Target | Susquehanna | $80.00 to $85.00 | |
| 2014-06-03 | Downgrade | Citigroup Inc. | Neutral to Sell | $65.00 |
| 2014-05-19 | Reiterated | FBR Capital | Outperform | $70 to $78 |
| 2014-05-19 | Boost Price Target | FBR & Co. | Outperform | $70.00 to $78.00 |
| 2014-04-25 | Reiterated Rating | Cantor Fitzgerald | Buy | $73.00 to $80.00 |
| 2014-04-23 | Reiterated Rating | Deutsche Bank | Hold | $67.00 |
| 2014-04-23 | Reiterated Rating | Citigroup Inc. | Hold | $65.00 |
| 2014-04-23 | Boost Price Target | Oppenheimer | $75.00 to $78.00 | |
| 2014-04-23 | Boost Price Target | Leerink Swann | Outperform | $71.00 to $78.00 |
| 2014-04-23 | Boost Price Target | Jefferies Group | Hold | $65.00 to $69.00 |
| 2014-04-10 | Boost Price Target | Susquehanna | Positive | $68.00 to $70.00 |
| 2014-02-05 | Boost Price Target | Leerink Swann | $68.00 to $71.00 | |
| 2014-02-05 | Upgrade | Citigroup Inc. | Sell to Neutral | $59.00 |
| 2014-01-23 | Upgrade | Credit Suisse | Neutral to Outperform | $72.00 to $70.00 |
| 2013-12-16 | Reiterated Rating | Deutsche Bank | Hold | $71.00 to $67.00 |
| 2013-12-16 | Upgrade | Susquehanna | Neutral to Positive | $60.00 to $68.00 |
| 2013-11-21 | Initiated Coverage | Morgan Stanley | Equal Weight | |
| 2013-11-18 | Initiated Coverage | Leerink Swann | Outperform | $68.00 |
| 2013-11-13 | Initiated Coverage | FBR & Co. | Outperform | $70.00 |
| 2013-10-27 | Reiterated Rating | BMO Capital Markets | Buy | $84.00 |
| 2013-10-23 | Boost Price Target | Jefferies Group | Hold | $66.00 to $68.00 |
| 2013-10-23 | Boost Price Target | Cantor Fitzgerald | Buy | $65.00 to $73.00 |
| 2013-10-23 | Boost Price Target | BMO Capital Markets | Market Perform | $56.00 to $62.00 |
| 2013-10-23 | Boost Price Target | Barclays | Overweight | $68.00 to $84.00 |
| 2013-10-23 | Downgrade | Monness Crespi & Hardt | Buy to Neutral | $70.00 |
| 2013-10-23 | Downgrade | Citigroup Inc. | Neutral to Sell | |
| 2013-10-16 | Boost Price Target | Deutsche Bank | Hold | $63.00 to $71.00 |
| 2013-10-09 | Reiterated Rating | Susquehanna | Neutral | $55.00 to $60.00 |
| 2013-10-08 | Reiterated Rating | JPMorgan Chase & Co. | Hold | $60.00 |
| 2013-10-08 | Boost Price Target | Deutsche Bank | Hold | $55.00 to $63.00 |
| 2013-09-24 | Reiterated Rating | Jefferies Group | Hold | $63.00 |
| 2013-09-24 | Boost Price Target | JPMorgan Chase & Co. | Neutral | $50.00 to $60.00 |
| 2013-09-16 | Reiterated Rating | Wedbush | Buy | $67.00 |
| 2013-09-16 | Boost Price Target | Jefferies Group | Hold | $63.00 |
| 2013-07-23 | Upgrade | Cantor Fitzgerald | Hold to Buy | $50 to $65 |
| 2013-05-30 | Reiterated | Monness Crespi & Hardt | Buy | $54 to $60 |
| 2013-04-23 | Reiterated | Cantor Fitzgerald | Hold | $45 to $50 |
| 2013-02-05 | Reiterated | Cantor Fitzgerald | Hold | $32 to $45 |
| 2013-01-04 | Reiterated | Barclays | Overweight | $51 to $60 |
| 2012-12-17 | Reiterated | Deutsche Bank | Hold | $40 to $38 |
| 2012-12-03 | Reiterated | Barclays | Overweight | $47 to $51 |
| 2016-06-29 | Upgrade | Morgan Stanley | Equal Weight to Overweight | $84.00 to $86.00 |
| 2016-06-28 | Initiated Coverage | Wolfe Research | Market Perform | $80.00 |
| 2016-06-28 | Reiterated Rating | Credit Suisse | Buy | |
| 2016-06-28 | Reiterated Rating | Credit Suisse Group AG | Buy | |
| 2016-06-20 | Reiterated Rating | Cowen and Company | Buy |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In CNC 566 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| Vanguard Group, Inc | 65.17M |
| Capital World Investors | 48.67M |
| BlackRock Inc. | 42.12M |
| FMR LLC | 34.33M |
| PRICE T ROWE ASSOCIATES INC /MD/ | 31.27M |
| STATE STREET CORP | 24.10M |
| JPMORGAN CHASE & CO | 20.69M |
| WELLINGTON MANAGEMENT CO LLP | 19.12M |
| Capital International Investors | 12.51M |
| Boston Partners | 11.53M |
| GEODE CAPITAL MANAGEMENT, LLC | 10.22M |
| Invesco Ltd. | 6.38M |
| AMERIPRISE FINANCIAL INC | 6.16M |
| NORTHERN TRUST CORP | 5.53M |
| BANK OF AMERICA CORP /DE/ | 4.98M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| NEIDORFF MICHAEL F Chairman, President and CEO | 6.19% (3625571) | BWS / CNC / |
| DITMORE ROBERT K | 0.81% (471917) | CNC / |
| Hunter Jesse N EVP, Chief Bus. Dev. Officer | 0.40% (233629) | CNC / |
| Thompson Tommy G | 0.32% (187914) | BCR / CGIX / CNC / CYTX / DOC / PURE / TXMD / UTHR / |
| BRINKLEY CYNTHIA J EVP, International Operations | 0.28% (163694) | CNC / |
| EPPINGER FREDERICK H | 0.27% (158737) | CNC / STC / THG / |
| Imholz Donald G EVP, Chief Information Officer | 0.26% (151599) | CNC / |
| JOSEPH PAMELA A | 0.24% (140534) | CNC / PAYX / TSS / USB / |
| SCHEFFEL WILLIAM N Exec VP, CFO & Treasurer | 0.24% (138362) | CNC / |
| Schwaneke Jeffrey A. SVP, Corp. Controller & CAO | 0.23% (132632) | CNC / |
| ROBERTS JOHN R | 0.18% (106913) | CNC / ENR / |
| STEWARD DAVID L | 0.18% (104021) | CNC / |
| Baldwin Kenneth Rone EVP, Insurance Group | 0.16% (92712) | CNC / |
| Williamson Keith H EVP, Secr. & General Counsel | 0.16% (92658) | CNC / PPL / |
| AYALA ORLANDO | 0.16% (92165) | CNC / |
| GOLDMAN CAROL Exec VP Chief Admin Officer | 0.12% (70876) | CNC / |
| BOWERS CHRISTOPHER D EVP, Markets | 0.11% (65908) | CNC / |
| BROOKS MARK J SVP, Chief Information Officer | 0.08% (48915) | CNC / |
| KROLL EDMUND E SVP Fin & Investor Relations | 0.08% (46279) | CNC / |
| HARROLD JASON M EVP, Specialty Comp. Bus. Unit | 0.08% (44329) | CNC / |
| GEPHARDT Richard A | 0.07% (42623) | CNC / CTL / F / SPR / X / |
| HITCHCOCK ROBERT T EVP Health Plans | 0.05% (26415) | CNC / |
| MINIFIE C DAVID EVP, Chief Marketing Officer | 0.04% (24031) | CNC / |
| ESCARRA VICKI B | 0.03% (15035) | CNC / HNT / |
| Isaak Christopher R SVP, Corporate Controller, CAO | 0.02% (14393) | CNC / VIAS / |
UM